GlaxoSmithKline's Covid-19 Therapy Receives Favorable Opinion From EMA
May 21 2021 - 8:40AM
Dow Jones News
By Jaime Llinares Taboada
GlaxoSmithKline PLC and Vir Biotechnology Inc. said Friday the
European Medicines Agency has issued a positive opinion on the use
of sotrovimab for the treatment of Covid-19.
GlaxoSmithKline said the EMA's Committee for Human Medicinal
Products reached its opinion following an analysis of studies which
evaluated sotrovimab as monotherapy for the early treatment of
Covid-19 in adults at high risk of hospitalization. Results of the
interim analysis demonstrated an 85% reduction in hospitalization
or death in those receiving sotrovimab compared to the placebo.
"As the Covid-19 pandemic continues and the virus generates new
variants of concern, including those that recently emerged in
India, the need for therapies that can slow the progression of
disease in patients who are at high risk for developing severe
complications remains a top priority," said Christopher Corsico,
GlaxoSmithKline's vice president for development.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
May 21, 2021 08:25 ET (12:25 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
